Who owns Kymera?
Kymera has been owned by affiliates of palladium equity partners, llc (collectively, “palladium”), a middle market private equity firm with over $3 billion in assets under management, since 2018. Palladium equity partners acquires kymera international and 5n’s antimony powder assets. The single platform is rebranded to promote global products, established as kymera international.Kymera has been owned by affiliates of Palladium Equity Partners, LLC (collectively, “Palladium”), a middle market private equity firm with over $3 billion in assets under management, since 2018.
Is Kymera public?
Kymera Therapeutics has successfully priced a public offering of $250. The offering includes both common stock and pre-funded warrants, indicating strong investor interest and flexibility in financing options. The gross proceeds to Kymera from the offering are expected to be approximately $250. Kymera, excluding the exercise of any pre-funded warrants and assuming no exercise of the underwriters’ option to purchase .Kymera Therapeutics enjoys unanimous support from analysts, with 20 buy ratings and no holds or sells. This bullish sentiment is further reflected in the target price range of $53.